sponsored
PatientsVille.com Logo

PatientsVille

Eplerenone Medical Research Studies

Up-to-date List of Eplerenone Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Eplerenone Medical Research Studies

Rank Status Study
1 Recruiting Eplerenone for the Treatment of Central Serous Chorioretinopathy
Condition: Central Serous Chorioretinopathy
Interventions: Drug: 25mg Eplerenone;   Drug: Placebo
Outcome Measures: Absence of sub-foveal (retinal) fluid based on spectral domain optical coherence tomography (OCT) measurement.;   Mean change in subfoveal fluid height based on OCT measurement
2 Recruiting The Effect of Eplerenone on Ischemia Reperfusion Injury in Human myoCARDium
Condition: Ischemia-reperfusion Injury
Interventions: Drug: Eplerenone;   Other: Aldosterone
Outcome Measures: contractile function after simulated ischemia and reperfusion in response to Eplerenone;   contractile function in response to Eplerenone vs Eplerenone and caffeine
3 Recruiting Eplerenone for Central Serous Chorioretinopathy
Condition: Central Serous Chorioretinopathy
Intervention: Drug: Eplerenone 50mg
Outcome Measures: Resolution of Sub-retinal Fluid;   Change in macular thickness;   Best Corrected Visual Acuity;   Change in choroidal thickness, both eyes;   Safety and Tolerability Characteristics
4 Recruiting Eplerenone in HIV Associated Abdominal Fat Accumulation
Condition: HIV
Interventions: Drug: Eplerenone and lifestyle;   Other: placebo and lifestyle
Outcome Measures: Insulin stimulated glucose uptake;   visceral adipose tissue;   liver fat;   intramyocellular lipid;   flow mediated vasodilation;   potassium;   hemoglobin A1c;   c-reactive protein;   plasminogen activator inhibitor 1;   adiponectin
5 Not yet recruiting Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Eplerenone
Outcome Measures: Change in average E' (averaged septal E' and lateral E');   Development of worsening diastolic function;   Development of worsening systolic function;   Change in septal E';   Change in lateral E';   Change in E/E';   Change in E/A;   Change in left atrial volume index;   Change in left ventricular ejection fraction (LVEF);   Biomarkers
6 Unknown  CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
Condition: Cardiomyopathy
Interventions: Drug: Eplerenone;   Drug: Placebo
Outcome Measures: Improvement in MVO2;   Reduction in major adverse cardiovascular events
7 Recruiting Eplerenone in CsA-Treated Recipients (EpleCsAT): Safety
Conditions: Chronic Kidney Insufficiency;   Kidney Transplantation
Intervention: Drug: Eplerenone
Outcome Measure: Occurence of an adverse event requiring the discontinuation of Eplerenone
8 Recruiting Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure
Condition: Heart Failure
Interventions: Drug: Eplerenone;   Drug: Placebo
Outcome Measures: First occurrence of cardiovascular mortality or heart failure hospitalization;   First occurrence of Cardiovascular (CV) mortality, heart failure (HF) hospitalization or Addition/Increase of HF medication due to HF worsening;   All-cause mortality;   CV mortality;   All-cause hospitalization;   HF hospitalization;   All-cause mortality or all-cause hospitalization;   HF mortality or HF hospitalization;   CV hospitalization;   Addition/Increase of HF medication due to HF worsening;   Fatal/non-fatal myocardial infarction;   Fatal/non-fatal stroke;   New onset atrial fibrillation/flutter;   New onset diabetes mellitus;   Worsening renal function (if it results in hospitalization);   Hospitalization for hyperkalemia;   Plasma BNP, Serum nt-BNP;   LVEF;   NYHA classification;   Specific activity scale (SAS)
9 Not yet recruiting PHOspholamban RElated CArdiomyopathy STudy - Intervention
Condition: Phospholamban Related Cardiomyopathy
Intervention: Drug: Eplerenone
Outcome Measures: LV enddiastolic volume, increase >10%, as measured by MRI;   LV ejection fraction, absolute decrease >5%, as measured by MRI;   RV enddiastolic volume, increase >10%, as measured by MRI;   RV ejection fraction, absolute decrease >5%, as measured by MRI;   late gadolinium enhancement, absolute increase >5%, as measured by MRI;   Change in ventricular premature complexes, increase >100% in combination with absolute number >1000/24 hrs (Holter monitoring);   Change in the occurrence of non-sustained ventricular tachycardia (Holter monitoring, exercise testing);   Change in QRS voltage, decrease >25% (ECG);   Change in symptoms/signs of heart failure and/or arrhythmias necessitating treatment according to the attending physician and likely due to arrhythmogenic cardiomyopathy;   (Change in) cardiovascular death, including sudden death, likely due to arrhythmogenic cardiomyopathy;   Change in biomarkers;   Change in QRS-axis on 12-lead ECG;   Change in conduction intervals (PR-interval, QRS-duration) on 12-lead ECG and SA-ECG;   Change in STT-segment on 12-lead ECG;   Development of global or regional dysfunction and structural alterations on MRI;   (Change in) Diagnosis of ARVC (according to task force criteria);   (Change in) Diagnosis of DCM;   Change in occurrence of sustained ventricular tachycardia or ventricular fibrillation;   (Change in) hospitalization for a cardiovascular reason
10 Recruiting The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease
Conditions: Tetralogy of Fallot;   Transposition of the Great Vessels With an Arterial Switch;   Single Ventricle With a Fontan Palliation
Intervention: Drug: Eplerenone
Outcome Measures: Change in serum markers of fibrosis.;   6 minute walk;   Quality of Life
11 Recruiting Comparison of Effects of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes
Conditions: Heart Failure;   Type 2 Diabetes;   Glucose Intolerance
Interventions: Drug: Eplerenone;   Drug: Spironolactone
Outcome Measures: Glycated hemoglobin;   Fasting glucose and lipid profile;   Plasma insulin;   Cortisol;   Adiponectin;   NT-proBNP;   PIIINP
12 Recruiting Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy
Condition: Hypertensive Left Ventricular Hypertrophy
Interventions: Drug: Aliskiren;   Drug: Eplerenone
Outcome Measures: reduction of left ventricular hypertrophy measured by magnetic resonance imaging;   Cardiovascular events
13 Recruiting The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)
Condition: CKD II-III
Interventions: Drug: Eplerenone;   Drug: Placebo
Outcome Measure: Angiotensin levels (pg/ml) of CKD II-III patients with DM II with Eplerenone additional to enalapril in comparison to patients who receive a placebo on top of enalapril therapy.
14 Recruiting Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects
Conditions: Ascites;   Cirrhosis
Intervention: Drug: Eplerenone
Outcome Measure: Ascites
15 Not yet recruiting CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression
Condition: Hypertension
Interventions: Drug: Eplerenone;   Drug: placebo
Outcome Measures: Change in LV mass index (g/m2) in ClC-Ka Gly/Gly83 patients and ClC-Ka Gly/Gly83 patients;   Change in LV relative wall thickness;   Change in N-terminal pro-brain natriuretic peptide (NT-proBNP);   Change in LV mass index (g/m2)
16 Unknown  Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?
Conditions: Hypertension;   Dialysis;   Hyperaldosteronism
Interventions: Drug: Eplerenone;   Drug: Placebo
Outcome Measure: Significant drop in blood pressure with Eplerenone when compared to placebo.
17 Recruiting The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension
Condition: Hypertension
Interventions: Drug: Eplerenone;   Drug: Amlodipine;   Procedure: Microneurography;   Procedure: Rhythmic handgrip exercise;   Procedure: Sustained hand grip;   Procedure: Forearm blood flow;   Procedure: Arm cycling exercise;   Procedure: Cold Pressor test
Outcome Measure: Muscle sympathetic nerve activity during exercise
18 Recruiting Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy
Condition: Central Serous Chorioretinopathy
Intervention: Drug: Eplerenone
Outcome Measure: Decrease of at least 10% in subretinal fluid thickness as measured by optical coherence tomography (OCT)
19 Recruiting Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone
Condition: Heart Failure
Interventions: Drug: BAY94-8862;   Drug: Eplerenone;   Drug: Placebo
Outcome Measures: The percentage of subjects with a relative decrease in N-terminal prohormone B-type natriuretic peptide of more than 30% from baseline to Visit 10;   Change in serum potassium
20 Recruiting Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
Condition: Heart Failure
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo;   Drug: Inspra (Eplerenone)
Outcome Measures: Relative decrease in N-terminal prohormone B-type natriuretic peptide (NT-proBNP);   Change in serum potassium;   Change in blood pressure;   Change in heart rate;   Number of participants with adverse events as a measure of safety and tolerability

These studies may lead to new treatments and are adding insight into Eplerenone etiology and treatment.

A major focus of Eplerenone research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Eplerenone